A paradigm shift for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer: a review of CDK inhibitors.

Autor: Fernandes MT; Faculdade de Medicina do ABC, Santo André, Brazil., Adashek JJ; College of Osteopathic Medicine of the Pacific, Western University of Health Sciences, Pomona, CA, USA., Barreto CMN; A Beneficência Portuguesa de São Paulo, São Paulo, Brazil., Spinosa ACB; Faculdade de Medicina do ABC, Santo André, Brazil., de Souza Gutierres B; Universidade Paulista, São Paulo, Brazil., Lopes G; Sylvester Comprehensive Cancer Center at the University of Miami, Miami, FL, USA., Del Giglio A; Faculdade de Medicina do ABC, Santo André, Brazil., Aguiar PN Jr; Faculdade de Medicina do ABC, Santo André, Brazil.

Publikováno v: Drugs in context [Drugs Context] 2018 Nov 05; Vol. 7, pp. 212555. Date of Electronic Publication: 2018 Nov 05 (Print Publication: 2018).